Trial Profile
Gemcitabine and Oxaliplatin in First Line Metastatic or Recurrent Nasopharyngeal Carcinoma (NPC).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Aug 2009
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Oxaliplatin (Primary)
- Indications Nasopharyngeal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sanofi
- 18 Aug 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jul 2008 The expected completion date for this trial is 1 Dec 2009 as reported by ClinicalTrials.gov.
- 18 Jun 2007 Status changed from recruiting to in progress.